The massive revenue and operating income growth confirm strong product uptake, but the lack of EPS and guidance limits conviction. Monitor the June 30 conference call for pipeline updates and any forward-looking commentary.
Price Chart
Executive Summary
Elite Pharmaceuticals reported fiscal year 2026 revenue of $148.9M, up 77% YoY, and operating income of $49.1M, up 151% YoY, driven by full-year contribution of Lisdexamfetamine and new product launches (Oxycodone Acetaminophen, Naltrexone, Phentermine). The strong operational performance marks a significant inflection, though no EPS or forward guidance was provided.
Key Financial Metrics
Key Facts
- Consolidated revenue for fiscal year ended March 31, 2026: $148.9 million, up $64.8M or ~77% vs prior year.
- Income from operations: $49.1 million, up $29.5M or ~151% vs prior year.
- Growth attributed to full-year contribution of Lisdexamfetamine, launch of Oxycodone Acetaminophen tablets, and exclusive Elite-label launches of Naltrexone and Phentermine tablets.
- No EPS, net income, or forward guidance provided in the press release.
- Conference call scheduled for June 30, 2026 at 11:30 AM EDT.
Financial Impact
Revenue increased by $64.8M and operating income increased by $29.5M year-over-year.
Risk Factors
- OTC listing (ELTP) with low liquidity and limited institutional coverage.
- No EPS or net income disclosed; profitability metrics remain unclear.
- Absence of forward guidance creates uncertainty about sustainability of growth.
- Historical filings on this ticker have not reliably predicted stock movement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-031103 |
| Exhibit: ex99-1.htm | 0001493152-26-031103 |
| Document: 0001493152-26-031103-index-headers.html | 0001493152-26-031103 |
| Document: 0001493152-26-031103-index.html | 0001493152-26-031103 |
| Document: 0001493152-26-031103.txt | 0001493152-26-031103 |
| 8-K Data (Synthetic) | 0001493152-26-031103 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $0.3600 | awaiting T+60 | — | $0.2371 (−34.14%) |
Jun 29, 2026 17w ago | 8-K | $0.3700 $0.2470 | ▼ −33.24% | ▼ −37.08% | $0.2371 (−35.92%) |
Jun 15, 2026 19w ago | 8-K | $0.3700 $0.2599 | ▼ −29.76% | ▼ −31.02% | $0.2371 (−35.92%) |
Jun 1, 2026 21w ago | 8-K | $0.3600 $0.2827 | ▼ −21.47% | ▼ −22.70% | $0.2371 (−34.14%) |
Apr 2, 2026 29w ago | 8-K | $0.3800 $0.3651 | ▼ −3.92% | ▼ −18.08% | $0.2371 (−37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers